Key result
Thyrotoxicosis treatment and dual-chamber pacemaker improve LVEF to 45% in a heart failure case.
Case Report (n=1)
Identifying and treating reversible aggravating factors such as thyrotoxicosis can markedly improve clinical status and left ventricular ejection fraction in patients with heart failure.
Answers are grounded in this paper and cite their sources.
May support reversible cardiomyopathy in thyrotoxicosis; hypothesis-generating and requires prospective confirmation before practice change.
Introduction Heart failure (HF) with reduced ejection fraction is a complex condition requiring comprehensive diagnostic work-up and management. Case presentation A 62-year-old male presented with resting HF and multiple syncopes. Medical history: former smoker, type 2 diabetes, advanced peripheral artery disease. Physical examination: congestive HF, obesity, discrete exophthalmia, grade 1 goitre, BP 110/70 mmHg, HR: 180 bpm. ECG: atrial fibrillation (AF), 180 bpm, RBBB, ST depression in anterolateral leads. CXR: pulmonary congestion, right pleural effusion. Blood analysis: D-dimer >5ng/ml, NTproBNP 12.900 pg/ml, hsTnI 550 ng/L, low TSH, fT3, fT4 4xULN. Cardiac echo: LVEF 20%, diffuse hypokinesis. HF symptom improvement with decongestion and rate control medication. Methimazole started on day 3. Intermittent conversion to sinus rhythm (SR) on day 7. ECG Holter (day 8–9): alternating moderate/high-rate AF and SR, 5–8 second sinus pauses and 1 syncope. LVEF 35% (day 9). Dual-chamber pacemaker implanted on day 10. Discharged on day 18. 2-months follow-up: LVEF 45%, NTproBNP 1.100 pg/ml, SR, HR 65–70 bpm, NYHA I HF. Conclusion Cardiac and non-cardiac aggravating factors can contribute to HF worsening. Unmasking these factors is essential, as specific treatments can markedly improve the patient's clinical status.
No takes yet. Share an insight, caveat, or question.
Cotoban et al. (2021) conducted a case report in Heart failure, atrial fibrillation, thyrotoxicosis (n=1). Decongestion, rate control, methimazole, and dual-chamber pacemaker was evaluated on Clinical status and LVEF improvement. Treatment of thyrotoxicosis and implantation of a dual-chamber pacemaker led to an improvement in LVEF from 20% to 45% and resolution of heart failure symptoms at 2 months.
Synapse has enriched 10 related papers. Consider them for comparative context: